Roche's KRAS drug divarasib shows strong lung cancer data at ESMO

Roche presented promising efficacy data for divarasib, a KRAS inhibitor for lung cancer, at ESMO. The data suggests a potential new treatment option, but regulatory approval and market impact remain uncertain. This is a notable clinical win for Roche in a competitive oncology space.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works